Paragon Capital Management Inc. Invests $1.01 Million in Boston Scientific Corporation $BSX

Paragon Capital Management Inc. bought a new position in Boston Scientific Corporation (NYSE:BSX) during the first quarter, HoldingsChannel.com reports. The institutional investor bought 16,173 shares of the medical equipment provider’s stock, valued at approximately $1,015,000.

Several other hedge funds have also added to or reduced their stakes in the business. FWL Investment Management LLC bought a new position in shares of Boston Scientific during the second quarter valued at about $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific in the 4th quarter valued at about $26,000. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 231 shares during the last quarter. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the 4th quarter valued at about $26,000. Finally, Bangor Savings Bank boosted its holdings in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the period. 89.07% of the stock is owned by institutional investors.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $44.30 on Tuesday. The business has a 50 day moving average of $54.37 and a 200 day moving average of $72.44. Boston Scientific Corporation has a 52 week low of $44.05 and a 52 week high of $109.50. The company has a market cap of $65.84 billion, a PE ratio of 18.53, a P/E/G ratio of 0.87 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock buyback plan on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In related news, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cheryl Pegus purchased 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BSX shares. Oppenheimer set a $90.00 price target on Boston Scientific in a research note on Thursday, April 23rd. Daiwa Securities Group cut shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Citigroup cut their price target on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. Finally, Mizuho lowered their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.